dexamethasone

AssetSmall moleculeAlso Vigadexa, OCS-01, Ciprofloxacin/Dexamethasone, Dexamethasone sodium phosphate

Glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive effects

Stage: Approved
Modality: Small molecule
Target: NF-κB signalling
Indications: 31
Trials: 2,108
Developers: 10

Indications

31

Burns
Approvedaccessdata.fda.gov7 Oct 2026
Conjunctivitis, Allergic
Approvedaccessdata.fda.gov7 Oct 2026
Diabetic macular edema
Approvedaccessdata.fda.gov7 Oct 2026

28 more

Targets and what it contains4
Owner and partners10
Trials2,108
Evidence for its targets5
Competitors12
Aging relevance1
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 56 sources